Reducing Palivizumab Dose Requirements Through Rational Dose Regimen Design.

ABSTRACT: Palivizumab for respiratory syncytial virus (RSV) immunoprophylaxis in premature infants poses a significant economic challenge. Although standard dosing of palivizumab results in unnecessary drug accumulation without additional clinical benefit, some clinicians have moved outside of evidence-based practice by implementing untested dose modifications, potentially jeopardizing efficacy. Using an industry-developed population pharmacokinetic model, this study evaluated the previously published alternate dosing regimens and developed a revised regimen that minimizes palivizumab dose requirements while maintaining established therapeutic concentrations. All published dose modifications resulted in unacceptably high proportions of infants not attaining minimum protective concentrations, comprom

SUBMITTER: Reuter SE 

PROVIDER: S-EPMC6363066 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature